CMS GENEROUS Model Pricing Structure: What Medicaid Programs and Life Science Companies Need to Know

Manatt Health analyzes the new GENEROUS Model announced by CMS, comparing its pricing metrics to previously used most-favored-nation (MFN) approaches and outlining key design elements and timeline. The piece examines participation opportunities and risks for both pharmaceutical manufacturers and state Medicaid programs, addressing outstanding design questions that affect drug pricing and reimbursement in Medicaid managed care.

Pharmacy · Managed Care · Finance

This is outside commentary from Manatt Health, not part of Medicaid Monitor's independently scored news coverage.

More from Manatt Health